Dr. Ueno on Liquid Biopsy

Naoto Tada Ueno, MD, PhD, FACP
Published: Monday, Dec 22, 2014

Naoto Tada Ueno, MD, PhD, FACP, from The University of Texas MD Anderson Cancer Center, discusses the advantages of liquid biopsy to detect and monitor tumor growth. 

It is difficult to subject patients to multiple traditional biopsies due to the potential risks and burden of the patient, explains Ueno.

Liquid biopsies, which use circulating tumor cells (CTCs) and fragments of tumor DNA, provide a bigger picture of biological changes at the metastatic site, without using invasive techniques.

Naoto Tada Ueno, MD, PhD, FACP, from The University of Texas MD Anderson Cancer Center, discusses the advantages of liquid biopsy to detect and monitor tumor growth. 

It is difficult to subject patients to multiple traditional biopsies due to the potential risks and burden of the patient, explains Ueno.

Liquid biopsies, which use circulating tumor cells (CTCs) and fragments of tumor DNA, provide a bigger picture of biological changes at the metastatic site, without using invasive techniques.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x